Methods and processes are provided to make clinoptilolite into a water-soluble solvolyzed form with electrolytes suitable for various administration routes for use in the detoxification and rejuvenation in environment arena, nutraceutical arena, and pharmaceutical arena This process includes oral, topical, tablet, pill formulas, biotech delivery and intravenous. Absorption of water-soluble solvolyzed clinoptilolite fragments can aid in detoxification by binding to heavy metals, viruses and environmental toxins and can reduce reactive oxygen species and inflammation related to metals. The process and method described can provide an increase in energy, increase in growth factors that aid in hair, skin, and nail growth, and can provide an increase in focus, concentration, and memory. Water-soluble solvolyzed, electrolyzed clinoptilolite fragments can be combined with one or more dietary supplements, including various vitamins, minerals, and sleep aids to rejuvenate the cells and the environment during and after detoxification.

The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400 C. and 800 C., preferably between 500 C. and 700 C., in particular preferably at 550 C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.

The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400 C. and 800 C., preferably between 500 C. and 700 C., in particular preferably at 550 C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.

Novel neuroprotective preparations of hemp oil and magnesium are disclosed herein. Antioxidant and anti-inflammatory activity of hemp oil (containing a broad-spectrum of beneficial phytochemicals) are combined with magnesium and has been found to reduce oxidative stress, upregulation of antioxidant enzyme systems, and the mitigation of NMDA-receptor hyperactivity. The synergistic effects of hemp oil and bioavailable magnesium are utilized to improve cognitive function, mood, stress tolerance, and reduce oxidative stress and inflammation. A highly-efficacious, lipophilic, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable and convenient intra-oral, or topical, anti-inflammatory, neurotrophic, and neuroprotective preparation. Additionally, methods of use are described, allowing for effective, safe, and convenient use for general (public) and clinical use, in both humans and animals.

Novel neuroprotective preparations of hemp oil and magnesium are disclosed herein. Antioxidant and anti-inflammatory activity of hemp oil (containing a broad-spectrum of beneficial phytochemicals) are combined with magnesium and has been found to reduce oxidative stress, upregulation of antioxidant enzyme systems, and the mitigation of NMDA-receptor hyperactivity. The synergistic effects of hemp oil and bioavailable magnesium are utilized to improve cognitive function, mood, stress tolerance, and reduce oxidative stress and inflammation. A highly-efficacious, lipophilic, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable and convenient intra-oral, or topical, anti-inflammatory, neurotrophic, and neuroprotective preparation. Additionally, methods of use are described, allowing for effective, safe, and convenient use for general (public) and clinical use, in both humans and animals.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

The present invention provides a film coated tablet comprising a first film coating layer comprising hydroxypropyl methylcellulose and a second film coating layer comprising polyvinyl alcohol, on a tablet containing choline alfoscerate as an active ingredient and magnesium aluminometasilicate as an additive; and a process for preparing the same.

The present invention provides a film coated tablet comprising a first film coating layer comprising hydroxypropyl methylcellulose and a second film coating layer comprising polyvinyl alcohol, on a tablet containing choline alfoscerate as an active ingredient and magnesium aluminometasilicate as an additive; and a process for preparing the same.

The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating and/or preserving food products and cut flowers, among other uses.

The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating and/or preserving food products and cut flowers, among other uses.